Novo Nordisk Pharmaceuticals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Novo Nordisk Pharmaceuticals
Names of Lobbyists
Firm Hired Amount Novo Nordisk Pharmaceuticals $3,540,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Copyright, Patent & Trademark,
- Medical Research & Clin Labs,
- Government Issues,
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009 H.R.1402 Catalyst to Better Diabetes Care Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 S.844 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009 H.R.4872 Health Care and Education Affordability Reconciliation Act of 2010 H.R.1 American Recovery and Reinvestment Act of 2009 S.1473 Catalyst to Better Diabetes Care Act of 2009 S.515 Patent Reform Act of 2009 H.R.1260 Patent Reform Act of 2009
RegulationsMentioned in 3 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Novo Nordisk Pharmaceuticals" in public comments on proposed federal regulations.
Mentions in Document Text
View all mentions data for Novo Nordisk Pharmaceuticals
- Toggle 1 USTR Request for Comments Concerning Free Trade Agreement With the Republic of Korea 2009
- Toggle 1 FDA Guidance for Industry: Technical Considerations for PEN, JET, and Related Injectors Intended for use With Drugs and Biological Products; Availability 2009
- Toggle 1 FDA International Conference on Harmonisation; Draft Guidance on Addendum to ICH S6; Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1); Availability 2009